Martin Hutchings

In this discussion, Stephen Schuster and Jason Westin from top cancer centers delve into the latest in CAR T-cell therapy for non-Hodgkin lymphoma. They explore the treatment landscape, strategies to manage toxicities, and the promise of allogeneic CAR-T products. Joining them, Stephen Ansell and Martin Hutchings share insights on the role of bispecific antibodies, comparing their efficacy against CAR T therapies. They also address unique challenges and exciting combinations with antibody-drug conjugates that could redefine treatment approaches.

Experts Dr Martin Hutchings and Dr Loretta Nastoupil discuss the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma. Topics include different agents, efficacy, tolerability, dose step up, treatment duration, challenges in generating order sets, patient experience, comparing immunotherapies, and side effect profiles.